• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Maxim Group initiated coverage on Panbela Therapeutics with a new price target

    3/10/21 9:33:23 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBLA alert in real time by email
    Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00
    Get the next $PBLA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBLA

    DatePrice TargetRatingAnalyst
    6/28/2021$10.00Buy
    Roth Capital
    More analyst ratings

    $PBLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Panbela Therapeutics with a new price target

    Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

    6/28/21 6:58:09 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Panbela Therapeutics with a new price target

    Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

    3/16/21 8:15:44 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Panbela Therapeutics with a new price target

    Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

    3/10/21 9:33:23 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PBLA
    SEC Filings

    View All

    $PBLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Panbela Provides Business Update and Reports Q3 2024 Financial Results

    MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,

    11/14/24 4:10:36 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

    MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

    10/31/24 8:00:00 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

    MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start

    9/24/24 8:00:00 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

    2/18/25 4:32:54 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

    2/4/25 4:02:40 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant

    8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

    1/22/25 4:02:43 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Nant Capital, Llc

    4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

    11/19/24 6:40:08 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Nant Capital, Llc

    3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

    10/29/24 7:38:18 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by V.P. of Finance & CFO Horvath Susan

    4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

    10/3/24 4:26:59 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Panbela Therapeutics Inc.

    SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

    10/29/24 7:40:55 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

    SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

    2/13/24 8:10:27 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

    SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

    2/14/23 2:45:11 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBLA
    Financials

    Live finance-specific insights

    View All

    Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

    MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

    10/31/24 8:00:00 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

    MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

    7/30/24 4:15:00 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

    MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

    5/1/24 4:15:00 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care